Common Contracts
2 similar Stockholders’ Agreement contracts by Sancilio Pharmaceuticals Company, Inc.
SANCILIO & COMPANY, INC. SECOND AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT MAY 21, 2014Stockholders’ Agreement • August 31st, 2015 • Sancilio Pharmaceuticals Company, Inc. • Pharmaceutical preparations • Delaware
THIS SECOND AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT is made and entered into as of this 21st day of May, 2014 by and among Sancilio & Company, Inc., a Delaware corporation (the “Company”), each holder of the Company’s Series A Preferred Stock, par value $0.01 per share (“Series A Preferred Stock”), listed on Schedule A, each holder of the Company’s Series B Preferred Stock, par value $0.01 per share (the “Series B Preferred Stock”), listed on Schedule A and each holder of the Company’s Series C Preferred Stock, par value $0.01 per share (the “Series C Preferred Stock” and, together with the Series A Preferred Stock and Series B Preferred Stock, the “Preferred Stock”) listed on Schedule A (such holders of Preferred Stock and any subsequent investors, or transferees, who become parties hereto as “Investors” pursuant to Subsections 8.1(a) or 8.2 below, the “Investors”) and each holder of the Company’s Common Stock, par value $0.01 per share (“Common Stock”) listed on Schedule B (toge
SANCILIO & COMPANY, INC. SECOND AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT MAY 21, 2014Stockholders’ Agreement • May 14th, 2015 • Sancilio Pharmaceuticals Company, Inc. • Pharmaceutical preparations • Delaware
THIS SECOND AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT is made and entered into as of this 21st day of May, 2014 by and among Sancilio & Company, Inc., a Delaware corporation (the “Company”), each holder of the Company’s Series A Preferred Stock, par value $0.01 per share (“Series A Preferred Stock”), listed on Schedule A, each holder of the Company’s Series B Preferred Stock, par value $0.01 per share (the “Series B Preferred Stock”), listed on Schedule A and each holder of the Company’s Series C Preferred Stock, par value $0.01 per share (the “Series C Preferred Stock” and, together with the Series A Preferred Stock and Series B Preferred Stock, the “Preferred Stock”) listed on Schedule A (such holders of Preferred Stock and any subsequent investors, or transferees, who become parties hereto as “Investors” pursuant to Subsections 8.1(a) or 8.2 below, the “Investors”) and each holder of the Company’s Common Stock, par value $0.01 per share (“Common Stock”) listed on Schedule B (toge
